| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
MicroRNAs (miRNAs) play important roles in the regulation of gene expression during cervical carcinogenesis. Four miRNAs (miR-126-3p, -20b-5p, -451a, and -144-3p) in cervical mucus were significantly upregulated in precancer and cancer compared with normal, and their expression levels correlated with the disease severity. miRNAs in cervical mucus are promising biomarkers for cervical cancer and its precursor lesions.
Next, we investigated the effects of enforced miR-126-3p expression in the cervical cancer cell line, HeLa. In miR-126-3p-transfected cells, p85b, p110a, p-PDK1, p- AKT, p-GSK3b, CyclinD1, MRCKa, ROCK1, and p- PLCg1 were downregulated, Bad and Bax were upregulated, whereas Bcl-xL expression was downregulated, resulting in increased caspase3/7 activity and apoptosis. High levels of miR-126-3p may inhibit cervical carcinogenesis, and targeting the PI3K/PDK1/AKT pathway via miR-126-3p could represent a new approach for treating patients with cervical cancer.
|
